<?xml version="1.0" encoding="UTF-8"?>
<p>Definitions and examples illustrating each of these population categories are included in Fig. 
 <xref rid="hep41310-fig-0001" ref-type="fig">1</xref>, with further details found in previous studies.
 <xref rid="hep41310-bib-0006" ref-type="ref">6</xref>, 
 <xref rid="hep41310-bib-0009" ref-type="ref">9</xref>, 
 <xref rid="hep41310-bib-0010" ref-type="ref">10</xref>, 
 <xref rid="hep41310-bib-0013" ref-type="ref">13</xref>, 
 <xref rid="hep41310-bib-0030" ref-type="ref">30</xref>, 
 <xref rid="hep41310-bib-0031" ref-type="ref">31</xref>, 
 <xref rid="hep41310-bib-0032" ref-type="ref">32</xref>, 
 <xref rid="hep41310-bib-0033" ref-type="ref">33</xref>, 
 <xref rid="hep41310-bib-0034" ref-type="ref">34</xref>, 
 <xref rid="hep41310-bib-0035" ref-type="ref">35</xref>, 
 <xref rid="hep41310-bib-0043" ref-type="ref">43</xref>, 
 <xref rid="hep41310-bib-0044" ref-type="ref">44</xref>, 
 <xref rid="hep41310-bib-0045" ref-type="ref">45</xref> The same definitions were applied to all studies in all countries. All studies among PWID were for current PWID, not ex‐PWID who are no longer injecting. Population‐ and country‐mixed samples were excluded from further analysis. Consequently, the analyses included a total of 2,521 prevalence studies on 48,931,779 individuals, among whom 459,598 individuals were antibody positive (Table 
 <xref rid="hep41310-tbl-0001" ref-type="table">1</xref>).
</p>
